Adverse Events

In the first 16-week period of phase B,

there were no significant differences in
adverse events between patients
receiving risperidone (groups 1 and 2)
and those receiving placebo (group 3)
In the second 16-week period of phase
B, there were no significant differences
in such adverse events between
patients who continued to receive
risperidone (group 1) and those who
discontinued risperidone and were
switched to placebo (group 2)
There were no significant differences
between patients who received
risperidone continuously for 32 weeks
(group 1) and those who received
placebo continuously for 32 weeks
(group 3)
A total of 11 serious adverse events
occurred during phase B
Three deaths occurred during phase
Aand 3 deaths (2 in patients receiving
risperidone and 1 in a patient receiving
placebo) occurred during phase B